|
1
|
Baigent C, Keech A, Kearney PM, Blackwell
L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, et
al: Efficacy and safety of cholesterol-lowering treatment:
Prospective meta-analysis of data from 90,056 participants in 14
randomised trials of statins. Lancet. 366:1267–1278.
2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kawashiri MA, Yamagishi M, Sakamoto T,
Takayama T, Hiro T, Daida H, Hirayama A, Saito S, Yamaguchi T,
Matsuzaki M and COSMOS Investigators: Impact of intensive lipid
lowering on lipid profiles over time and tolerability in stable
coronary artery disease: Insights from a subanalysis of the
coronary atherosclerosis study measuring effects of rosuvastatin
using intravascular ultrasound in Japanese subjects (COSMOS).
Cardiovasc Ther. 31:335–343. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wakabayashi K, Nozue T, Yamamoto S,
Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A,
Miyake S, et al: Efficacy of statin therapy in inducing coronary
plaque regression in patients with low baseline cholesterol levels.
J Atheroscler Thromb. 23:1055–1066. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nissen SE, Nicholls SJ, Sipahi I, Libby P,
Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC,
Tardif JC, et al: Effect of very high-intensity statin therapy on
regression of coronary atherosclerosis: The ASTEROID trial. JAMA.
295:1556–1565. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Matoba T and Egashira K:
Nanoparticle-mediated drug delivery system for cardiovascular
disease. Int Heart J. 55:281–286. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen L, Nakano K, Kimura S, Matoba T,
Iwata E, Miyagawa M, Tsujimoto H, Nagaoka K, Kishimoto J, Sunagawa
K and Egashira K: Nanoparticle-mediated delivery of pitavastatin
into lungs ameliorates the development and induces regression of
monocrotaline-induced pulmonary artery hypertension. Hypertension.
57:343–350. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kubo M, Egashira K, Inoue T, Koga J, Oda
S, Chen L, Nakano K, Matoba T, Kawashima Y, Hara K, et al:
Therapeutic neovascularization by nanotechnology-mediated
cell-selective delivery of pitavastatin into the vascular
endothelium. Arterioscler Thromb Vasc Biol. 29:796–801.
2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Oda S, Nagahama R, Nakano K, Matoba T,
Kubo M, Sunagawa K, Tominaga R and Egashira K:
Nanoparticle-mediated endothelial cell-selective delivery of
pitavastatin induces functional collateral arteries (therapeutic
arteriogenesis) in a rabbit model of chronic hind limb ischemia. J
Vasc Surg. 52:412–420. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tsukie N, Nakano K, Matoba T, Masuda S,
Iwata E, Miyagawa M, Zhao G, Meng W, Kishimoto J, Sunagawa K and
Egashira K: Pitavastatin-incorporated nanoparticle-eluting stents
attenuate in-stent stenosis without delayed endothelial healing
effects in a porcine coronary artery model. J Atheroscler Thromb.
20:32–45. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Starr T, Bauler TJ, Malik-Kale P and
Steele-Mortimer O: The phorbol 12-myristate- 13-acetate
differentiation protocol is critical to the interaction of THP-1
macrophages with Salmonella Typhimurium. PLoS One.
13(e0193601)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Daley JM, Thomay AA, Connolly MD, Reichner
JS and Albina JE: Use of Ly6G-specific monoclonal antibody to
deplete neutrophils in mice. J Leukoc Biol. 83:64–70.
2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee PY, Wang JX, Parisini E, Dascher CC
and Nigrovic PA: Ly6 family proteins in neutrophil biology. J
Leukoc Biol. 94:585–594. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Leuschner F, Dutta P, Gorbatov R,
Novobrantseva TI, Donahoe JS, Courties G, Lee KM, Kim JI, Markmann
JF, Marinelli B, et al: Therapeutic siRNA silencing in inflammatory
monocytes in mice. Nat Biotechnol. 29:1005–1010. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Banfi C, Baetta R, Gianazza E and Tremoli
E: Technological advances and proteomic applications in drug
discovery and target deconvolution: Identification of the
pleiotropic effects of statins. Drug Discov Today. 22:848–869.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Helin-Salmivaara A, Lavikainen PT,
Korhonen MJ, Halava H, Martikainen JE, Saastamoinen LK, Virta L,
Klaukka T and Huupponen R: Pattern of statin use among 10 cohorts
of new users from 1995 to 2004: A register-based nationwide study.
Am J Manag Care. 16:116–122. 2010.PubMed/NCBI
|
|
17
|
Jackevicius CA, Mamdani M and Tu JV:
Adherence with statin therapy in elderly patients with and without
acute coronary syndromes. JAMA. 288:462–467. 2002.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bhavane R, Badea C, Ghaghada KB, Clark D,
Vela D, Moturu A and Annapragada A, Johnson GA, Willerson JT and
Annapragada A: Dual-energy computed tomography imaging of
atherosclerotic plaques in a mouse model using a liposomal-iodine
nanoparticle contrast agent. Circ Cardiovasc Imaging. 6:285–294.
2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Weissleder R, Nahrendorf M and Pittet MJ:
Imaging macrophages with nanoparticles. Nat Mater. 13:125–138.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Mulder WJ and Fayad ZA: Nanomedicine
captures cardiovascular disease. Arterioscler Thromb Vasc Biol.
28:801–802. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Leuschner F and Nahrendorf M: Molecular
imaging of coronary atherosclerosis and myocardial infarction:
Considerations for the bench and perspectives for the clinic. Circ
Res. 108:593–606. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Michalska M, Machtoub L, Manthey HD, Bauer
E, Herold V, Krohne G, Lykowsky G, Hildenbrand M, Kampf T, Jakob P,
et al: Visualization of vascular inflammation in the
atherosclerotic mouse by ultrasmall superparamagnetic iron oxide
vascular cell adhesion molecule-1-specific nanoparticles.
Arterioscler Thromb Vasc Biol. 32:2350–2357. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Nagahama R, Matoba T, Nakano K,
Kim-Mitsuyama S, Sunagawa K and Egashira K: Nanoparticle-mediated
delivery of pioglitazone enhances therapeutic neovascularization in
a murine model of hindlimb ischemia. Arterioscler Thromb Vasc Biol.
32:2427–2434. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kimura S, Egashira K, Chen L, Nakano K,
Iwata E, Miyagawa M, Tsujimoto H, Hara K, Morishita R, Sueishi K,
et al: Nanoparticle-mediated delivery of nuclear factor kappaB
decoy into lungs ameliorates monocrotaline-induced pulmonary
arterial hypertension. Hypertension. 53:877–883. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kimura S, Egashira K, Nakano K, Iwata E,
Miyagawa M, Tsujimoto H, Hara K, Kawashima Y, Tominaga R and
Sunagawa K: Local delivery of imatinib mesylate
(STI571)-incorporated nanoparticle ex vivo suppresses vein graft
neointima formation. Circulation. 118(14 Suppl):S65–S70.
2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nagaoka K, Matoba T, Mao Y, Nakano Y,
Ikeda G, Egusa S, Tokutome M, Nagahama R, Nakano K, Sunagawa K and
Egashira K: A new therapeutic modality for acute myocardial
infarction: Nanoparticle-mediated delivery of pitavastatin induces
cardioprotection from ischemia-reperfusion injury via activation of
PI3K/Akt pathway and anti-inflammation in a rat model. PLoS One.
10(e0132451)2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nakano K, Egashira K, Masuda S, Funakoshi
K, Zhao G, Kimura S, Matoba T, Sueishi K, Endo Y, Kawashima Y, et
al: Formulation of nanoparticle-eluting stents by a cationic
electrodeposition coating technology: Efficient nano-drug delivery
via bioabsorbable polymeric nanoparticle-eluting stents in porcine
coronary arteries. JACC Cardiovasc Interv. 2:277–283.
2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Matoba T, Koga JI, Nakano K, Egashira K
and Tsutsui H: Nanoparticle-mediated drug delivery system for
atherosclerotic cardiovascular disease. J Cardiol. 70:206–211.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang W, Yancey PG, Su YR, Babaev VR,
Zhang Y, Fazio S and Linton MF: Inactivation of macrophage
scavenger receptor class B type I promotes atherosclerotic lesion
development in apolipoprotein E-deficient mice. Circulation.
108:2258–2263. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
McLaren JE, Michael DR, Ashlin TG and
Ramji DP: Cytokines, macrophage lipid metabolism and foam cells:
Implications for cardiovascular disease therapy. Prog Lipid Res.
50:331–347. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Leon C, Hill JS and Wasan KM: Potential
role of acyl-coenzyme A: Cholesterol transferase (ACAT) inhibitors
as hypolipidemic and antiatherosclerosis drugs. Pharm Res.
22:1578–1588. 2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Berman JP, Farkouh ME and Rosenson RS:
Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin
Emerg Drugs. 18:193–205. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Katsuki S, Matoba T, Nakashiro S, Sato K,
Koga J, Nakano K, Nakano Y, Egusa S, Sunagawa K and Egashira K:
Nanoparticle-mediated delivery of pitavastatin inhibits
atherosclerotic plaque destabilization/rupture in mice by
regulating the recruitment of inflammatory monocytes. Circulation.
129:896–906. 2014.PubMed/NCBI View Article : Google Scholar
|
